GDTC
GDTC
NASDAQ · Biotechnology

Cytomed Therapeutics Ltd

$0.82
+0.04 (+4.55%)
As of May 16, 2:28 AM ET ·
Financial Highlights (FY 2026)
Revenue
356.3K
Net Income
-4,365,342
Gross Margin
95.2%
Profit Margin
-1,227.1%
Rev Growth
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 95.2% 48.2% 48.2% 48.2%
Operating Margin -1,231.9% -13.7% -13.7% -16.6%
Profit Margin -1,227.1% -13.7% -12.0% -16.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 356.3K 1.99M 1.82M 1.81M
Gross Profit 339.3K 960.7K 880.3K 874.9K
Operating Income -4,389,782 -272,039 -249,417 -301,800
Net Income -4,365,342 -271,887 -219,394 -295,477
Gross Margin 95.2% 48.2% 48.2% 48.2%
Operating Margin -1,231.9% -13.7% -13.7% -16.6%
Profit Margin -1,227.1% -13.7% -12.0% -16.3%
Rev Growth +6.4% +1.5% -4.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 357.5K 2.19M 1.92M 2.35M
Total Equity 4.85M 8.12M 8.19M 8.32M
D/E Ratio 0.07 0.27 0.23 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,210,805 -443,981 -374,843 -381,153
Free Cash Flow -242,138 -341,295 -221,285